BioSenic Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
BIOS
- Investments
-
1
BioSenic General Information
Description
Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.
Contact Information
Website
www.biosenic.comCorporate Office
- Avenue Leon Champagne, 3
- 1480 Saintes
- Belgium
Corporate Office
- Avenue Leon Champagne, 3
- 1480 Saintes
- Belgium
BioSenic Timeline
BioSenic Stock Performance
As of 26-May-2026, BioSenic’s current market cap is $1.52M.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.52M | 1.27M |
BioSenic Financials Summary
As of 31-Dec-2025, BioSenic has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2025 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 31,833 | 31,833 | 29,052 | 37,466 |
| Revenue | 0 | 0 | ||
| EBITDA | (1,493) | (1,493) | (5,299) | (29,566) |
| Net Income | (5,159) | (31,140) | ||
| Total Assets | 3,993 | 3,993 | 4,934 | 10,567 |
| Total Debt | 0 | 0 | 28,850 | 31,129 |
BioSenic Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BioSenic Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
BioSenic Comparisons
Industry
Financing
Details
BioSenic Competitors (3)
One of BioSenic’s 3 competitors is Aurimi Therapeutics, a Venture Capital-Backed company based in Woburn, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aurimi Therapeutics | Venture Capital-Backed | Woburn, MA | ||||
| ImCyse | Formerly VC-backed | Liege, Belgium | ||||
| Equaly | Venture Capital-Backed | Louvain-la-Neuve, Belgium |
BioSenic Patents
BioSenic Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4455672-A1 | Method and kit for diagnosing and monitoring chronic graft-versus-host disease (cgvhd) using particular cytokine biomarkers | Pending | 26-Apr-2023 | ||
| WO-2024223904-A1 | Method and kit for establishing and monitoring treatments of chronic graft-versus-host disease (cgvhd) using cytokine or chemokines biomarkers | Inactive | 26-Apr-2023 | ||
| EP-3988093-A1 | Use of an arsenic compound for treating a cytokine storm | Inactive | 22-Oct-2020 | ||
| EP-4527462-A2 | Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune / inflammatory diseases in humans or animals | Pending | 03-Apr-2020 | ||
| AU-2021247142-A1 | Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune/inflammatory diseases in humans or animals | Inactive | 03-Apr-2020 | A61P11/00 |
BioSenic Signals
BioSenic Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BioSenic Acquisitions (1)
BioSenic’s most recent deal was a Merger/Acquisition with Bone Therapeutics. The deal was made on 25-Oct-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Bone Therapeutics | 25-Oct-2022 | Merger/Acquisition | Biotechnology |
BioSenic ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
BioSenic FAQs
-
When was BioSenic founded?
BioSenic was founded in 2006.
-
Where is BioSenic headquartered?
BioSenic is headquartered in Saintes, Belgium.
-
What is the size of BioSenic?
BioSenic has 7 total employees.
-
What industry is BioSenic in?
BioSenic’s primary industry is Drug Discovery.
-
Is BioSenic a private or public company?
BioSenic is a Public company.
-
What is BioSenic’s stock symbol?
The ticker symbol for BioSenic is BIOS.
-
What is the current market cap of BioSenic?
The current market capitalization of BioSenic is $1.52M.
-
Who are BioSenic’s competitors?
Aurimi Therapeutics, ImCyse, and Equaly are competitors of BioSenic.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process